Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Shareholder feedback

This is absolutely the case, and has been made here numerous times.

That's why I regard with apprehension the shift management has been making in statements, PRs, and other materials (see new website) that PTSC is shifting to a M&A company. The reality is that it is losing licensing revenue, not gaining other business revenue, to make the M&A a higher percentage of PTSC business. This is not a designed shift, it is a forced one.





Share
New Message
Please login to post a reply